The Roddenberry Foundation has awarded $1m to Elypta and $500,000 to five finalists for early-stage ventures contributing to United Nations Development Goals.
Elypta, a Swedish diagnostic company, aim to provide the first metabolism-based liquid biopsy for early detection of cancer. Elypta’s lead product, the Miriam, is a glycosaminoglycan kit manufauctered under contract by Merck KGaA.
Karl Bergman, CEO and co-founder of Elypta, told Medical Device Network that the award is recognition of what the company has achieved and shows the faith in its technology for cancer detection.
